RLAY Relay Therapeutics, Inc.

$18.88▼ -0.94% Healthcare Other
Volume 1.12M Avg Volume (10D) 3.29M
Key Metrics & Fundamentals
Market Cap
$4.14B
P/E Ratio
–
Div Yield
–%
52W Range
4.05 - 21.27
% vs 50 MA
-1.65%
% vs 200 MA
43.68%
RSI-14
48.9
MACD Histogram
-0.0600
Beta (1Y vs SPY)
1.55
Free Cash Flow
-$54.11M
Gross Rev
$350,000
Gross Profit
$350,000
EBITDA
-$90.46M
COGS
–
Operating Exp
$91.17M
Operating Income
-$90.82M
EBIT
-$90.82M
Pretax Income
-$83.71M
Net Income
-$83.71M
EPS (Diluted)
-0.41
Price & Volume History
Loading chart…
Recent News
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing
MT Newswires · Sep 9, 2026 8:21 PM
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Zacks · Sep 3, 2026 2:32 PM
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Motley Fool · Sep 2, 2026 5:20 PM
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
GlobeNewswire · Sep 1, 2026 8:46 PM
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
Investor's Business Daily · Aug 21, 2026 7:43 PM
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?
Simply Wall St. · Aug 20, 2026 12:16 AM
Relay Therapeutics Insider Sold Shares Worth $349,734, According to a Recent SEC Filing
MT Newswires · Aug 18, 2026 8:30 PM
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing
MT Newswires · Aug 18, 2026 8:28 PM
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
Zacks · Aug 18, 2026 7:43 AM
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Zacks · Aug 17, 2026 1:56 PM
Financial Overview - Income Statement Quarterly

See RLAY's money flow as a full page

Social Sentiment
Avg +0.70 · 2 posts
DiscussionTradeRelay Therapeutics RLAY
r/wallstreetbets · Jun 29, 2026
The post discusses the stock's performance and expresses optimism about its potential.
positive +0.80
NewsEarningsPriceTargetDD$RLAY reversal:
r/wallstreetbets · Nov 21, 2024
The post highlights a potential rebound driven by oversold conditions and earnings revisions, indicating positive sentiment.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙